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Abstract
Background: Adipose tissue lipid storage and processing capacity can be a key factor for obesity-related metabolic
disorders such as insulin resistance and diabetes. Lipid uptake is the first step to adipose tissue lipid storage. The aim of this
study was to analyze the gene expression of factors involved in lipid uptake and processing in subcutaneous (SAT) and
visceral (VAT) adipose tissue according to body mass index (BMI) and the degree of insulin resistance (IR).
Methods and Principal Findings: VLDL receptor (VLDLR), lipoprotein lipase (LPL), acylation stimulating protein (ASP), LDL
receptor-related protein 1 (LRP1) and fatty acid binding protein 4 (FABP4) gene expression was measured in VAT and SAT
from 28 morbidly obese patients with Type 2 Diabetes Mellitus (T2DM) or high IR, 10 morbidly obese patients with low IR,
10 obese patients with low IR and 12 lean healthy controls. LPL, FABP4, LRP1 and ASP expression in VAT was higher in lean
controls. In SAT, LPL and FABP4 expression were also higher in lean controls. BMI, plasma insulin levels and HOMA-IR
correlated negatively with LPL expression in both VAT and SAT as well as with FABP4 expression in VAT. FABP4 gene
expression in SAT correlated inversely with BMI and HOMA-IR. However, multiple regression analysis showed that BMI was
the main variable contributing to LPL and FABP4 gene expression in both VAT and SAT.
Conclusions: Morbidly obese patients have a lower gene expression of factors related with lipid uptake and processing in
comparison with healthy lean persons.
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Introduction
The prevalence of obesity has increased over recent decades
and it is now considered a major health problem [1]. Obesity is
usually related to a number of co-morbidities, such as Type 2
Diabetes Mellitus (T2DM), insulin resistance (IR), cardiovascular
disease or dyslipidemia, though there exist metabolically healthy
obese patients without these obesity-related complications [1,2]. It
has been proposed that the expansion capacity of the adipose
tissue rather than the adipose tissue size could be, at least in part,
responsible for these inter-individual differences [3], and fat
accumulation in the visceral adipose tissue (VAT) is a higher risk
factor for the development of clinical complications of obesity than
is the subcutaneous fat depot [4]. Thus, correct lipid storage and
processing in the adipose tissue is crucial since if this process fails,
an excess of circulating free fatty acids (FFA) will be taken up by
non-adipose tissues, leading to metabolic complications such as IR
and T2DM [3].
FFA entry into the adipocyte is the first step to lipid storage. The
triglycerides transported in triglyceride-rich lipoproteins (TRL),
i.e. chylomicrons and VLDL, are lipolyzed by lipoprotein lipase
(LPL) to FFA, which are then taken up by the adipocyte. In
peripheral tissues, such as adipose tissue, the rate-limiting step for
triglyceride catabolism or FFA storage is catalyzed by LPL, which
is bound to glycosaminoglycans at the luminal side of the capillary
endothelium. LPL is the main gatekeeper enzyme for the entry
and reesterification of FFA in adipose tissue [5].
In addition to LPL-catalyzed hydrolysis of triglycerides it is
worth noting that TRL as well as lipase-hydrolyzed TRL remnants
can also be whole-particle internalized directly by cells via LDL
receptor family member proteins such as VLDL receptor
(VLDLR) and LDL receptor-related protein-1 (LRP1) [6]. The
VLDLR has a primary role in the anchorage of TRLs, thereby
facilitating subsequent triglyceride hydrolysis by LPL and FFA
entry into underlying tissues [7]. In addition, VLDLR and LPL
have a reciprocal regulation since LPL enhances the binding of
TRL to the VLDLR [5] and, at the same time, VLDLR regulates
LPL activity, as shown in vldlr-/- mice, where LPL expression is
reduced [7]. LRP1 interacts with apoE-enriched chylomicron and
VLDL remnants [8] and it is stimulated by insulin in adipocytes,
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ester from remnant lipoproteins [9]. Murine studies with
adipocyte-specific inactivation of the LRP1 gene have shown that
LRP1 expression in these cells plays an important role in obesity
development since these mice displayed a delayed postprandial
lipid clearance and were resistant to diet-induced obesity [10].
Intracellularly, FFA are bound to cytoplasmic fatty acid binding
proteins (FABPs). These FABPs direct FFA into the different
metabolic pathways [11]. Adipocyte fatty acid-binding protein (A-
FABP or FABP4 or aP2) is a small lipid-binding protein, highly
expressed in adipose tissue and also expressed in macrophages. It
is one of the most abundant cytoplasmic proteins in mature
adipocytes [11] and its function has been associated with insulin
sensitivity, lipid metabolism and inflammation [12].
Adipose tissue secretes a number of key molecules for regulation
of lipid metabolism. The acylation stimulating protein (ASP), which
stimulates triglyceride synthesis, is a small protein synthesized by
adipose tissue and it is the result of the posttranslational
modification of the complement factor C3. ASP stimulates
reesterification of FFA into triglycerides in adipocytes and
fibroblasts [13], reduces endogenous FFA production by inhibiting
hormone-sensitive lipase [14], and stimulates intracellular uptake of
glucose by adipocytes, fibroblasts, and muscle cells [13].
The aim of this study was to analyze the mRNA expression of
genes related with lipid uptake and processing in the visceral
(VAT) and subcutaneous adipose tissue (SAT) of lean healthy
controls, obese persons, morbidly obese patients with low IR and
morbidly obese patients with high IR or T2DM to determine any
differences between these phenotypes. To date, only a few human
studies have been undertaken simultaneously in the two tissues,
and ours is the first to compare the gene expression of this cluster
of genes between these groups of patients.
Results
The anthropometric and biochemical variables of the morbidly
obese patients, the obese persons and the lean healthy controls are
summarized in Table 1.
The mRNA expression of the genes studied in the VAT was
greater in the lean controls than in the morbidly obese patients
and/or the obese patients, as summarized in Table 2. Specifically,
LPL gene expression was significantly higher in lean controls than
in the other study groups. FABP4 gene expression was significant
higher in lean controls and in obese persons than in the two groups
of morbidly obese patients. We observed that LRP1 gene
expression was greater in lean controls compared to the morbidly
obese groups and finally, C3/ASP gene expression was signifi-
cantly higher in lean controls than in the other study groups.
In the SAT, the gene expression differences between groups
were less than in the VAT, though the tendency was the same as
that seen in VAT: a higher mRNA expression in lean controls
than in the other study groups. Only FABP4 and LPL gene
Table 1. Anthropometric and biochemical characteristics of the morbidly obese patients, and the obese and lean healthy subjects.
MO HIR/T2DM(n=28) MO LIR (n=10) Obese (n=10) Lean (n=12) p
Age (years) 42.7768.50 38.3069.35 42.38618.67 44.58610.96 0.158
%male/female 25/75 30/70 25/75 41.7/58.3 0.751
Weight (Kg) 143.41624.03 136.44628.51 82.00611.79 68.42612.12 0.000
BMI (Kg/m
2) 53.7767.11 50.2067.97 31.6861.70 24.4962.47 0.000
Waist (cm) 139.83614.66 130.40613.60 97.3866.91 85.04610.47 0.000
Hip (cm) 153.83612.68 148.65617.63 114.2564.40 99.9265.48 0.000
Ratio Waist/Hip 0.9160.08 0.8860.10 0.8560.07 0.8560.08 0.151
Insulin (mUI/mL) 24.58612.67 12.5863.35 9.2262.81 7.1162.35 0.000
Glucose (mmol/L) 6.3261.58 4.8060.43 5.0060.42 4.6660.52 0.000
Uric acid (mmol/L) 376.70692.16 370.97656.09 214.72645.57 252.29650.37 0.000
Cholesterol(mmol/L) 5.0462.30 4.5861.09 5.1961.12 5.2160.97 0.451
TG (mmol/L) 1.7360.99 1.1960.74 1.6760.90 0.9960.34 0.012
FFA (mmol/L) 0.5560.20 0.5060.25 0.6360.18 0.5060.23 0.279
HDL-C (mmol/L) 1.1460.26 1.0860.24 1.4660.22 1.4960.41 0.003
LDL-C (mmol/L) 3.2660.95 2.5160.52 2.7960.87 3.1460.61 0.157
GOT (units/L) 21.22611.74 20.3066.04 17.7565.04 21.9264.36 0.334
GPT (units/L) 43.41620.10 47.0069.87 40.63610.27 42.58610.27 0.437
GGT (units/L) 37.39621.49 37.50611.53 24.3866.74 25.7569.57 0.024
HOMA-IR 6.6863.49 2.7060.66 2.0660.64 1.4860.50 0.000
SBP (mmHg) 145.09621.23 136.22623.18 129.25614.93 109.00621.20 0.001
DBP (mmHg) 84.18616.02 82.33612.86 79.7567.98 74.82620.99 0.205
Leptin (ng/mL) 58.99618.50 66.82639.00 14.72614.04 14.37617.19 0.000
Adiponectin(ng/mL) 9.1264.28 9.2162.87 15.0165.88 24.70618.30 0.003
Values are presented as means 6 s.d. p value represents statistical significance between the study groups determined by Kruskal-Wallis test. MO HIR/T2DM, morbidly
obese patients with high insulin resistance or with type 2 diabetes mellitus; MO LIR, morbidly obese patients with low insulin resistance; BMI, body mass index; TG,
triglycerides; FFA, free fatty acids; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; GOT, glutamic oxalacetic transaminase; GPT, glutamic pyruvate transaminase; GGT, c–
glutamyltransferase; HOMA-IR, Homeostasis Model Assessment of insulin resistance; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure.
doi:10.1371/journal.pone.0024783.t001
Adipose Tissue Gene Expression in Obesity
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e24783expression was significantly different between the study groups,
noting a great difference between mRNA levels in lean controls
and the morbidly obese groups in the SAT (Table 2).
Comparison of the gene expression levels between the VAT and
the SAT in each study group showed a tendency to a higher
mRNA expression in the SAT than in the VAT for all genes
studied, except for C3/ASP gene expression which tended to be
lower in the SAT than in the VAT. More specifically, LRP1 gene
expression was significantly higher in SAT than in VAT in the
obese (p=0.018), MO LIR/T2DM (p=0.007) and MO HIR
(p=0.007) patient groups; LPL gene expression was significantly
greater in SAT than in VAT in the obese (p=0.012) and MO
HIR/T2DM (p=0.002) groups. FABP4 gene expression was
higher in SAT than in VAT (p=0.053) in the MO HIR/T2DM
group. In contrast, ASP gene expression was significantly lower in
SAT than in VAT in the MO LIR/T2DM group (p=0.000), in
lean healthy controls (p=0.003) and in the obese group
(p=0.012).
Correlations were analyzed between the mRNA expression level
and BMI, plasma insulin level, HOMA-IR and plasma triglyceride
levels in the VAT and the SAT (Tables 3 and 4). VAT LPL and
FABP4 mRNA expression showed a significant inverse correlation
with BMI, HOMA-IR and plasma insulin levels (p,0.01). LPL
gene expression in the SAT also correlated inversely with BMI
(p,0.01), plasma insulin levels, HOMA-IR and triglyceride levels
(p,0.05). FABP4 gene expression in the SAT only correlated
negatively with BMI (p,0.01) and HOMA-IR (p,0.05).
A multiple linear regression analysis was carried out to evaluate
the contribution of the different variables in LPL and FABP4 gene
expression in the VAT and the SAT (Tables 5 and 6). BMI,
HOMA-IR, plasma insulin and triglyceride levels, age and gender
were included as independent variables and LPL and FABP4 gene
expression as dependent variables. The only variable that
remained significantly associated with LPL and FABP4 gene
expression in both the VAT and in the SAT was the BMI.
Analysis was also made of the association between mRNA levels
of the studied genes. Significant positive correlations were found in
both VAT and SAT between the mRNA levels of the different
genes: VLDLR mRNA levels correlated positively with LPL,
FABP4 and LRP1 mRNA levels; FABP4 correlated positively with
LRP1 and LPL; and ASP correlated positively with LRP1
(Table 7). SAT LPL gene expression correlated significantly with
Table 2. mRNA expression levels of the genes studied in subcutaneous adipose tissue and visceral adipose tissue in the lean
healthy controls, obese subjects and morbidly obese patients.
MO HIR/T2DM (n=28) MO LIR (n=10) Obese (n=10) Lean (n=12) p
LPL VAT 2.86762.239 3.90662.323 3.02261.483 6.48262.744 0.001
SAT 4.30662.022* 5.84162.932 5.97562.053* 6.77264.199 0.049
FABP4 VAT 11.99667.349 12.58367.868 22.24169.134 26.078611.712 0.001
SAT 14.77665.425 14.16764.685 20.33866.939 24.467611.668 0.010
ASP VAT 3.22362.186 2.13561.411 2.33660.646 4.17161.714 0.046
SAT 1.33760.995* 1.05660. 442 1.10360.312* 1.34161.078
1 0.929
LRP1 VAT 0.38160.120 0.26960.110 0.41160.099 0.45860.329 0.074
SAT 0.49860.228* 0.40360.140* 0.58060.141* 0.53960.262 0.196
VLDLR VAT 0.48160.299 0.62460.291 0.64060.305 0.81860.746 0.457
SAT 0.57260.272 0.62960.294 0.84860.264 0.95960.969 0.198
Values are presented as means 6 s.d. p value represents statistical significance between the study groups determined by Kruskal-Wallis test.
*p,0.05 between SAT and VAT. MO HIR/T2DM, morbidly obese patients with high insulin resistance or with type 2 diabetes mellitus; MO LIR, morbidly obese patients
with low insulin resistance; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue. mRNA-level results are expressed as the expression ratio relative to
Cyclophilin A gene expression by calculating 2
2DCt, according to the manufacturer’s guidelines.
doi:10.1371/journal.pone.0024783.t002
Table 3. Correlations between the visceral adipose tissue
mRNA expression levels of the genes studied and the BMI,
triglycerides, insulin and HOMA-IR in all study subjects.
BMI Insulin HOMA-IR TG
LPL 20.450
a 20.329
a 20.324
a 20.226
b
FABP4 20.529
a 20.336
a 20.334
a 20.199
LRP1 20.022 0.041 0.129 20.047
VLDLR 20.213 20.162 20.221 0.048
ASP 0.060 0.187 0.170 0.045
Correlations were determined by Spearman’s correlation coefficient test.
aP ,0.01.
bP ,0.05;
BMI, Body Mass Index; HOMA-IR, Homeostasis Model Assessment of insulin
resistance; TG, triglycerides.
doi:10.1371/journal.pone.0024783.t003
Table 4. Correlations between the subcutaneous adipose
tissue mRNA expression levels of the genes studied and the
BMI, triglycerides, insulin and HOMA-IR in all study subjects.
BMI Insulin HOMA-IR TG
LPL 20.320
a 20.215
b 20.231
b 20.270
b
FABP4 20.365
a 20.139 20.195
b 20.119
LRP1 20.127 20.006 0.149 20.025
VLDLR 20.206 20.102 20.142 20.077
ASP 0.127 0.164 0.189 0.059
Correlations were determined by Spearman’s correlation coefficient test.
aP ,0.01;
bP ,0.05.
BMI, Body Mass Index; HOMA-IR, Homeostasis Model Assessment of insulin
resistance; TG, triglycerides.
doi:10.1371/journal.pone.0024783.t004
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same was seen with FABP4 (Fig. 1b), LRP1 (Fig. 1c) and VLDLR
(Fig. 1d) gene expression in VAT and SAT (p,0.001).
Discussion
Our results indicate that the greater the degree of obesity the
lower the gene expression of genes related with lipid processing in
adipose tissue (LPL, FABP4, ASP and LRP1), both visceral and
subcutaneous, though more obviously in the VAT.
Both LRP1 and VLDLR are members of the LDL receptor
family and participate in TRL LPL hydrolysis and TRL - remnant
clearance. Studies dealing with LRP1 expression in human
adipose tissue are scarce. Masson et al. recently reported that
LRP1 mRNA expression in human VAT is increased in obese
patients with respect to lean controls [15]. In contrast, we observed
a tendency for lower LRP1 gene expression in the VAT of
morbidly obese patients compared to lean controls. Of note,
however, is the different patient groups in the studies, since our
patient group covered a greater range of degrees of obesity and
included an extremely obese patient group while the study by
Masson compared morbidly obese patients with a lower BMI than
our patients vs. lean controls, for whom no clinical information
was provided, so these data have to be considered with caution.
Animal models have shown that VLDLR is highly expressed in
adipose tissue [16], but no studies have yet explored VLDLR
expression in human adipose tissue, at least as far as we are aware.
This, therefore, is the first study to report mRNA expression in
human VAT and SAT in both lean healthy subjects and in obese
patients. Studies with VLDLR knock-out mice have linked
VLDLR with obesity. When vldlr
2/
2 mice were fed a high-fat
diet, they remained lean whilst their wild-type littermates
developed obesity. Moreover, vldlr
2/
2 mice experienced a
reduction in adipocyte size, suggesting reduced adipocyte
triglyceride storage, and their LPL activity was reduced [17,18].
These results highlight the important role of VLDLR in TRL
hydrolysis and clearance and triglyceride storage in adipose tissue.
Concordantly, in humans VLDLR deficiency has been reported
and affected patients were also underweight [19]. In addition,
VLDLR variants have been associated with a lower BMI [20], but
no research has been done on how this mutation can affect
VLDLR expression or function. In our study we did observe a
tendency towards a lower VLDLR gene expression as the BMI
increased. Studies of human VLDLR regulation are few [16] and
we are conscious of the limitations in our study deducing a
mechanistic hypothesis. Nonetheless, our study represents a first
approach in the study of VLDLR in human adipose tissue and
further studies will be necessary to understand the relationship
between VLDLR in human adipose tissue, obesity and insulin
resistance.
Intracellularly, FABPs are believed to sequester and direct FFA
and their derivatives to different metabolic pathways, thus playing
an important role in fatty acid metabolism and avoiding
intracellular lipotoxicity [7]. Several studies have shown a higher
gene expression of FABP4 in the SAT than in the VAT of obese
subjects [21,22]. Concordantly, we observed the same tendency in
morbidly obese patients. However, other authors failed to find a
significant difference between FABP4 gene expression in SAT and
VAT [23]. We found that FABP4 gene expression was
significantly lower in the two morbidly obese groups than in
obese and lean subjects in the VAT and in the SAT. In a previous
study with obese normoglycemic, obese glucose intolerant, obese
diabetic patients and lean controls, a significant difference was
only found in the SAT between normoglycemic obese and glucose
intolerant obese female patients [23]. However, we found no
differences between the groups according to the degree of IR and
multiple regression analysis showed that BMI was the only variable
explaining the expression levels of FABP4, in both VAT and SAT.
Table 5. Multiple regression analysis for LPL gene expression in VAT and SAT, as dependent variable, in all the study subjects.
LPL_VAT (R=0.434;R
2=0.189) LPL_SAT (R=0.302; R
2=0.091)
b P CI 95% b P CI 95%
BMI 20.434 0.000 20.120 to20.039 20.302 0.012 20.106 to 20.013
Insulin 20.089 0.525 - 0.012 0.935 -
HOMA-IR 20.090 0.524 - 20.055 0.712 -
TG 20.087 0.454 - 20.198 0.105 -
VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; CI, confidence interval; BMI, body mass index; HOMA-IR, Homeostasis Model Assessment of insulin
resistance; TG, triglycerides.
doi:10.1371/journal.pone.0024783.t005
Table 6. Multiple regression analysis for FABP4 gene expression in VAT and SAT, as dependent variable, in all the study subjects.
FABP4_VAT (R=0.516;R
2=0.266) FABP4_SAT (R=0.368;R
2=0.135)
b P CI 95% b P CI 95%
BMI 20.516 0.000 20.518 to 20.218 20.368 0.002 20.339 to 20.079
Insulin 20.007 0.956 - 0.124 0.392 -
HOMA-IR 20.026 0.845 - 0.056 0.704 -
TG 20.021 0.852 - 20.061 0.611 -
VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; CI, confidence interval; BMI, body mass index; HOMA-IR, Homeostasis Model Assessment of insulin
resistance; TG, triglycerides.
doi:10.1371/journal.pone.0024783.t006
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carried out in just women with a lower BMI than our morbidly
obese patients, so it is likely that the BMI effect on FABP4 mRNA
expression is only noticeable in patients with a very high BMI. Our
group has previously shown that gene expression of FABP4 was
lower in morbidly obese persons than in lean persons in SAT [24].
In the present study was also included a group of non morbidly
obese persons with a low IR and showed that in this group of
patients with a lower BMI, the expression levels of FABP4 were
more similar to the group of healthy lean persons.
When there is excessive supply of nutrients, the adipose tissue
fatty acids are reesterified in triglycerides to be stored in adipose
tissue. ASP has been shown to be a powerful activator of this
process in adipocytes, mainly due to a greater activity of
diacylglycerol acyltransferase (DGAT), to greater entry of glucose
into the cell (necessary for glycerol synthesis) via greater
externalization of the GLUT receptors, and finally, inhibition of
hormone sensitive lipase (HSL) [13,14]. In addition, ASP
indirectly increases LPL activity [25]. Plasma ASP levels are
Table 7. Correlations between mRNA levels of the studied
genes in both visceral and subcutaneous adipose tissue.
LPL FABP4 LRP1 VLDLR ASP
ASP 20.053 20.106 0.399
a 20.003
VLDLR 0.615
a 0.419
a 0.396
a 0.119
LRP1 0.182 0.268
b 0.304
2 0.413
a
FABP4 0.723
a 0.299
b 0.430
a 0.197
LPL 0.619
a 0.198 0.705
a 20.039
Correlations were determined by Spearman’s correlation coefficient test.
aP ,0.01;
bP ,0.05.
Upper table represents correlations between mRNA levels of the different genes
in the VAT and the lower table represents correlations between mRNA levels of
the different genes in the SAT. VAT, visceral adipose tissue; SAT, subcutaneous
adipose tissue.
doi:10.1371/journal.pone.0024783.t007
Figure 1. Linear relationship determined by Spearman’s correlation coefficient test between (a) LPL gene expression in VAT and
LPL gene expression in SAT, (b) FABP4 gene expression in VAT and FABP4 gene expression in SAT, (c) LRP1 gene expression in VAT
and LRP1 gene expression in SAT and (d) VLDLR gene expression in VAT and VLDLR gene expression in SAT. VAT, visceral adipose
tissue; SAT, subcutaneous adipose tissue.
doi:10.1371/journal.pone.0024783.g001
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feature of elevated plasma ASP levels, as ASP is increased in
subjects with diabetes or polycystic ovary syndrome, even in the
absence of obesity [26]. But, since ASP has an autocrine effect in
adipose tissue, the use of plasma ASP levels is not the best method
to estimate adipose ASP production and its metabolic effect and
the in situ measurement of ASP production would have a greater
biological significance. ASP is produced in the adipose tissue by
the posttranslational cleavage of C3 complement factor [13]. Few
studies have examined C3 gene expression in adipose tissue [27–
31]. Our study is the first to compare the ASP precursor (C3) gene
expression in SAT and VAT from morbidly obese patients with
low IR and with high IR or T2DM, obese patients with low IR
and lean healthy subjects. Koistinen et al. found that overweight
patients, with and without T2DM, had a higher C3 gene
expression than lean healthy controls in the SAT [29]. However,
we found no significant differences between our study groups in
SAT C3 gene expression, but lean controls had higher VAT ASP
mRNA levels than the obese groups. We also saw that ASP gene
expression was greater in VAT than SAT, in agreement with
earlier studies [28,30]. VAT has a lower response capacity to ASP
and it has been proposed that the higher expression levels of its
precursor may be a compensatory mechanism against its low
response capacity [28,30].
LPL plays a major role in lipid metabolism and transport. The
availability of VLDL-derived fatty acids for energy needs and
adipocyte storage is dependent upon hydrolytic activity of LPL, and
to a lesser extent, endothelial lipase [5]. Insulin has a major effect on
LPL regulation in adipose tissue since in mature adipocytes insulin
not only increases the level of LPL mRNA but also regulates LPL
activity through both posttranscriptional and posttranslational
mechanisms [5,32]. Glucose also increases adipose tissue LPL
activity but, unlike insulin, glucose does not affect the level of LPL
mRNA[5,33].Inourstudythe patientswho had highlevelsofIRor
T2DM only experienced a slight reduction in LPL expression in
comparison with the other groups and the BMI was the main
variable associated with LPL mRNA levels, inversely. Thus, we
think the cause of this reduction in LPL expression is more probably
the increase in BMI and the hypertrophy or hyperplasia of the
adipose tissue rather than the degree of IR or the presence of
T2DM. Moreover, there are marked variations in the activity of
LPL in adipose tissue depots in humans. The steady-state mRNA
levels for LPL, as well as LPL mass, are lower in VAT than SAT.
Insulin increases the levels of LPL mRNA and LPL activity in
abdominal SAT but not VAT [34,35]. In our study we noted the
same results. This could be because the specific LPL activity is
greater in VAT than in SAT [36].
Thus, in our study subjects, as the BMI rose there was a drop in
mRNA expression of the genes studied, particularly LPL and
FABP4. This suggests that as the BMI increases the lipid storage
capacity in adipose tissue could decrease, which could be related
with the development of the IR that later appeared in these
patients, as proposed by others [37]. Accordingly, our results
support the following hypothesis: Under normal conditions, in the
presence of excess energy the adipose tissue is entrusted with
channeling this excess and storing the nutrients, at the expense of
increasing its volume. In the obese state, the adipose tissue is
submitted to a continuous energy surplus, such that over time the
lipid storage capacity of this tissue can be surpassed and the
adipose tissue, enable to respond to this excess, could reduce the
expression of genes involved in lipid processing and storage. If this
occurs, the adipose tissue might begin working incorrectly, leading
over time to metabolic disorders. Therefore, our study shows that
adipose tissue gene expression is different in subjects with different
BMI which indicates a different transcriptional regulation.
Nevertheless, further studies analyzing the activity and concen-
trations of these molecules will be necessary to confirm this
hypothesis.
In conclusion, our results show that morbidly obese patients
have a lower gene expression of factors related with lipid uptake
and processing in comparison with healthy lean persons, and that
this reduction is not dependent on the degree of insulin resistance.
Materials and Methods
Subjects and study design
The study was undertaken in 38 severely morbidly obese persons
(BMI=52.8367.41 kg/m
2), 10 obese patients (BMI=31.686
1.70 kg/m
2) and 12 healthy lean controls (BMI=24.4962.47
kg/m
2). Patients were excluded if they had cardiovascular disease,
arthritis, acute inflammatory disease, infectious disease, renal
disease or were receiving drugs that could alter the lipid profile or
the metabolic parameters at the time of inclusion in the study. All
participants gave their informed written consent and the study was
reviewed and approved by the Ethics and Research Committee.
The morbidly obese patients were divided in two groups: 10
patients with neither impaired glucose tolerance nor T2DM and
low insulin resistance [homeostasis model assessment of insulin
resistance (HOMA-IR) ,4.7] (MO LIR), and 28 patients with
high insulin resistance or T2DM (MO HIR/T2DM). The cut-off
point for the HOMA-IR was taken from previous studies carried
out in a healthy population with no carbohydrate metabolism
disorders [38].
Laboratory measurements
Before surgery and after an overnight fast, blood samples were
obtained from the antecubital vein and placed in vacutainer tubes
(BD vacutainer
TM, London, UK). The serum was separated by
centrifugation for 10 min at 4000 rpm and immediately frozen at
280uC until analysis. Serum glucose, cholesterol, triglycerides
and HDL cholesterol were measured in a Dimension autoana-
lyzer (Dade Behring Inc., Deerfield, IL) by enzymatic methods
(Randox Laboratories Ltd., UK). The LDL cholesterol was
calculated from the Friedewald equation. Insulin was quantified
by radioimmunoassay supplied by BioSource International,
Camarillo, S.A. Leptin and adiponectin were analyzed by
enzyme immunoassay (ELISA) kits (respectively: DSL, Webster,
TX, and DRG Diagnostics GmbH, Germany). The homeostasis
model assessment of insulin resistance (HOMA-IR) was calculat-
ed from fasting insulin and glucose with the following equation:
HOMA-IR=fasting insulin (mIU/mL)6fasting glucose (mmol/
L)/22.5 [39].
Visceral and subcutaneous adipose tissue RNA isolation
and real-time quantitative PCR
VAT and abdominal SAT were obtained during bariatric
surgery in the morbidly obese patients or during hiatal hernia
surgery in lean healthy controls and obese patients. The biopsy
samples were washed in physiological saline and immediately
frozen in liquid nitrogen. Biopsy samples were maintained at
280uC until analysis.
Total RNA isolation from adipose tissues was obtained using
RNeasy Lipid Tissue Mini Kit (Qiagen GmbH, Germany). The
purity of the RNA was determined by the 260/280 absorbance
ratio on the Nanodrop. The integrity of total purified RNA was
checked by denaturing agarose gel electrophoresis and ethidium
bromide staining. For first-strand cDNA synthesis, a constant
amount of 1 mg of total RNA was reverse transcribed using
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(Roche, Mannheim, Germany). Gene expression was assessed by real-
time PCR using an Applied Biosystems 7500 Fast Real-Time PCR
System (Applied Biosystems, Darmstadt, Germany) with TaqMan
technology. The reaction was performed, following the manufactur-
er’s protocol, in a final volume of 25 ml. The cycle program consisted
of an initial denaturing of 10 min at 95 uC, then 40 cycles of 15 sec
denaturing phase at 95uC, and 1 min annealing and extension phase
at 60uC. The commercially available and prevalidated TaqMan
primer/probe sets used in human sampl e sw e r ea sf o l l o w s :C y c l o ph i l i n
A (4326316E, RefSeq. NM_021130.3) used as endogenous control for
the target gene in each reaction [40], LPL (Hs00173425_m1, RefSeq.
NM_000237.2), FABP4 (Hs01086177_m1, Refseq. NM_001442.2),
LRP1 (Hs00233899_m1, Refseq. NM_002332.2), VLDLR
(Hs01045922_m1, Refseq. NM_003383.3) and C3/ASP
(Hs00163811_m1, Refseq. NM_000064.2). A threshold cycle (Ct
value) was obtained for each amplification curve and a DCt value was
first calculated by subtracting the Ct value for human Cyclophilin A
cDNA from the Ct value for each sample and transcript. Fold changes
compared with the endogenous control were then determined by
calculating 2
2DCt, and expression results are expressed as the
expression ratio relative to Cyclophilin A gene expression for humans,
according to the manufacturer’s guidelines. Inter-assay variability
(coefficient of variation) of the housekeeping gene was less than 0.5%.
All samples were quantified in triplicate and positive and negative
controls were included in all the reactions.
Statistical analysis
The results are given as the mean 6 SD. Comparisons of the
anthropometric and biochemical characteristics as well as the
mRNA expression levels between the study groups were made
with a non-parametric test (Kruskal–Wallis). Differences in mRNA
expression levels between the SAT and VAT were analyzed by the
Wilcoxon test. The Spearman correlation coefficients were
calculated to evaluate the association between the study variables.
Values were considered to be statistically significant when P,0.05.
The analyses were performed with SPSS (Version 15.0 for
Windows; SPSS Iberica, Madrid, Spain).
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